A 2023 analysis by the Institute for Clinical and Economic Review suggests that GLP-1 drugs are cost-effective in the long run, considering the reduced expenses related to obesity complications
The melatonin (5mg), L-Theanine, and Magnesium Citrate in the formula have favorable safety profiles for regular use in healthy adults
This typically results in reduced conversion rates, increased customer acquisition costs, and a longer payback period for marketing expenditures
Foundayo is FDA-approved for: Weight loss in adults with obesity or overweight with at least one weight-related health condition (such as type 2 diabetes) One of the key differentiators for Foundayo is its administration: It is the only GLP-1 pill for weight loss that can be taken any time of day, with or without food
Market launch: Manufacturing scale-up, distribution, and pharmacy availability